Search results

  1. Lloyd W. Coutee

    Will SABMiller Be Able To See Off AB Inbev?

    SABMiller has rejected AB InBev's bid at GBP 42.15, but under UK takeover rules, AB InBev still has until Wednesday to sweeten it. If AB InBev sweetens its offer, it probably will not be by much: it already seems to have the support of 40.5% of SABMiller's shares.
  2. Lloyd W. Coutee

    MCD is in big trouble. May not exist in 5 years

    There has been a theory going around that Chick-Fil-A will be the biggest threat to McDonald's over the next decade or so. Do you actually give a sh*t about it?
  3. Lloyd W. Coutee

    Investing Ratios You Need To Know for valuing a company.

    Earnings Per Share, Price To Earnings Ratio, Price to Sales Ratio. Which would you add and why?
  4. Lloyd W. Coutee

    Will $TWTR come back?

    While cutting jobs is intended to improve the company's efficiency and is often viewed as good news for investors, some shareholders are not viewing it positively.
  5. Lloyd W. Coutee

    $TSLA

    $TSLA Daily chart looks horrible, 14 RSI trending down, oversold, but broke 221, and can retest 185
  6. Lloyd W. Coutee

    Will $TWTR come back?

    As I mentioned on Friday, those late and chasing on $TWTR are not being rewarded and is normal after the strong buying volume dropped off
  7. Lloyd W. Coutee

    MCD is in big trouble. May not exist in 5 years

    This looks like a good spot to short $MCD.
  8. Lloyd W. Coutee

    $TSLA

    Still valued at nearly $30 billion despite no profit and increasing competition from other EV manufacturers.
  9. Lloyd W. Coutee

    MCD is in big trouble. May not exist in 5 years

    One University of California, Berkley study found that low-wage workers receive an estimated $127.8 billion in federal aid, and $25 billion in state aid. Responding to pressure, McDonald's announced in April that it would increase employee wages by more than 10 percent across 1,500...
  10. Lloyd W. Coutee

    Will $TWTR come back?

    After looking at the daily again, be very careful. Could end up red or doji before uptrend continue next week. But I am still bullish .
  11. Lloyd W. Coutee

    Does Technical Trading Really Work?

    In practice, technical analysis is a way to find high-probability setups in reaction to the market -- trading setups that factor in potential price barriers such as supply, demand and market mechanics and that give the trader cues about the market move with the highest likelihood. Charts can't...
  12. Lloyd W. Coutee

    $TSLA

    This stock tested 260 twice this year and spit it out, 200 by years end competition is increasing.
  13. Lloyd W. Coutee

    Does Technical Trading Really Work?

    Is technical analysis the Holy Grail for investors? Or is it just tea leaf reading? One of the most biting criticisms of technical analysis is the idea that there's no way past prices can be a crystal ball for future prices.
  14. Lloyd W. Coutee

    Will $TWTR come back?

    The news train has been nonstop here since CEO announcement was made, excellent PR machine. Seems $TWTR is coming back.
  15. Lloyd W. Coutee

    MCD is in big trouble. May not exist in 5 years

    I think bullish technical breakout in progress. Broke out above 101 resistance level, and holding. Upside target is 105-106 range.
  16. Lloyd W. Coutee

    The Biotech Bubble.

    biotechs on the brink of big breakdown? 3+ year trendline getting tested repeatedly here
  17. Lloyd W. Coutee

    $TSLA

    Very annoying when the street is quite likely right. "Tesla Shares Are Headed for a Big Selloff"
  18. Lloyd W. Coutee

    The Biotech Bubble.

    In this choppy mkt, fortunes will be made by nimble traders riding biotech swings. But it's like trying to catch fish in a hurricane.
  19. Lloyd W. Coutee

    $TSLA

    $TSLA continues to go sideways. I am in the camp it will revisit 192. Mkt tanks even more it will break sideways trend.
  20. Lloyd W. Coutee

    The Biotech Bubble.

    The problem with the broad-based selling, however, is not all stocks in the sector are overvalued—including many of its leaders. Amgen is now trading at 14 times its 2015 estimated earnings, while Biogen is trading at 17 times earnings, and Gilead Sciences at a mere 8 times 2015 earnings. All...
Back
Top